Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Raw Materials (2022 - 2024)

Atara Biotherapeutics' Raw Materials history spans 3 years, with the latest figure at $964000.0 for Q4 2024.

  • For Q4 2024, Raw Materials fell 58.72% year-over-year to $964000.0; the TTM value through Dec 2024 reached $964000.0, down 58.72%, while the annual FY2024 figure was $964000.0, 58.72% down from the prior year.
  • Raw Materials reached $964000.0 in Q4 2024 per ATRA's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $4.4 million in Q1 2024 to a low of $964000.0 in Q4 2024.
  • Average Raw Materials over 3 years is $2.3 million, with a median of $2.3 million recorded in 2023.
  • The largest YoY upside for Raw Materials was 229.38% in 2024 against a maximum downside of 58.72% in 2024.
  • A 3-year view of Raw Materials shows it stood at $1.2 million in 2022, then skyrocketed by 92.34% to $2.3 million in 2023, then crashed by 58.72% to $964000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATRA's Raw Materials are $964000.0 (Q4 2024), $1.7 million (Q3 2024), and $3.6 million (Q2 2024).